(neo)adjuvant therapy, 5-α reductase inhibitors, Androgen antagonists, Article of the Month, ASCO GU2026, ASCO GU21, ASCO GU22, ASCO2026, ASCO21, AUA21, BCG, BCG therapy, BCG-unresponsive disease, Bladder cancer, Bladder neoplasms, Bladder-sparing therapy, Bladder-sparing trimodality, Chemoradiotherapy, Clinical pathways, Clinical staging, Collaborative care, Comorbidity, Cystectomy, disitamab vedotin, Early recurrence patterns, EAU21, EAU22, EAU26, EMUC21, EMUC22, ENERGIZE trial, EORTC, ERBB2, ERCC2, ESMO 2026, ESMO21, ESOU21, ESOU22, Gene expression analysis, Guidelines, Hematuria, HER2, High-risk NMIBC, Highlight of the Month, Immune checkpoint, Immune checkpoint blockade, Immunoregulation, Immunotherapy, Intravesical therapy, Laparoscopic radical cystectomy, Masterclass, Masterclass on MIBC, Masterclass on NMIBC, Meta-analysis, Metastatic urothelial cancer, MIBC, Microscopic haematuria, Molecular subtypes, Multiparametric MRI, muscle-invasive bladder cancer, Nadofaragene firadenovec, Neoadjuvant, Neoadjuvant chemotherapy, Neoplasm recurrence, Nephroureterectomy, NIBC, nivolumab, NMIBC, Non-visible haematuria, Non–muscle-invasive bladder cancer, Nuclear matrix protein 22, Oncologic outcomes, Open radical cystectomy, Optical coherence, pathologic complete response, PD-L1, Pembrolizumab, perioperative checkpoint inhibition, PET, PLND, Postoperative complications, POUT trial, Prevention & control, Quality of life, Radical cystectomy, Radio-chemotherapy, Randomized controlled trial, RARC, RAZOR Trial, Recurrence, Robotic, Robotic prostatectomy, Robotic radical cystectomy, Robotic surgery, segmental ureterectomy, Summer reads, Surgical video, Surgical videos, Systematic review, targeted therapy, tislelizumab, Tomography, Transitional cell, Transitional cell carcinoma, Tregs, upper tract urothelial carcinoma, Urinary bladder neoplasms, Urinary diversion, Urological surgery, UROonco24, UROonco25, Urothelial cancer, Urothelium, UROwebinar, UTUC, UTUC stagging, Webinar, WUTSUP-02